Home Cart 0 Sign in  
X

[ CAS No. 2417-73-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 2417-73-4
Chemical Structure| 2417-73-4
Chemical Structure| 2417-73-4
Structure of 2417-73-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 2417-73-4 ]

Related Doc. of [ 2417-73-4 ]

Alternatived Products of [ 2417-73-4 ]

Product Details of [ 2417-73-4 ]

CAS No. :2417-73-4 MDL No. :MFCD03425900
Formula : C9H9BrO2 Boiling Point : -
Linear Structure Formula :- InChI Key :QKASDIPENBEWBU-UHFFFAOYSA-N
M.W : 229.07 Pubchem ID :2734813
Synonyms :

Calculated chemistry of [ 2417-73-4 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 3
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 50.56
TPSA : 26.3 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.97 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.33
Log Po/w (XLOGP3) : 2.43
Log Po/w (WLOGP) : 2.22
Log Po/w (MLOGP) : 2.7
Log Po/w (SILICOS-IT) : 2.71
Consensus Log Po/w : 2.48

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.96
Solubility : 0.249 mg/ml ; 0.00109 mol/l
Class : Soluble
Log S (Ali) : -2.63
Solubility : 0.543 mg/ml ; 0.00237 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.74
Solubility : 0.0419 mg/ml ; 0.000183 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.85

Safety of [ 2417-73-4 ]

Signal Word:Danger Class:8
Precautionary Statements:P260-P264-P270-P280-P301+P312+P330-P301+P330+P331-P303+P361+P353-P304+P340+P310-P305+P351+P338+P310-P362+P364-P405-P501 UN#:3261
Hazard Statements:H302+H312-H314 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 2417-73-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 2417-73-4 ]
  • Downstream synthetic route of [ 2417-73-4 ]

[ 2417-73-4 ] Synthesis Path-Upstream   1~17

  • 1
  • [ 2417-73-4 ]
  • [ 773837-37-9 ]
  • [ 5597-04-6 ]
Reference: [1] Journal of Organic Chemistry, 2017, vol. 82, # 2, p. 1114 - 1126
  • 2
  • [ 2417-73-4 ]
  • [ 143-33-9 ]
  • [ 5597-04-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2003, vol. 46, # 3, p. 345 - 348
  • 3
  • [ 2417-73-4 ]
  • [ 5597-04-6 ]
Reference: [1] Chemistry - A European Journal, 2012, vol. 18, # 5, p. 1383 - 1400
  • 4
  • [ 89-71-4 ]
  • [ 2417-73-4 ]
YieldReaction ConditionsOperation in experiment
100% With N-Bromosuccinimide; dibenzoyl peroxide In tetrachloromethane for 1.5 h; Reflux (2) Add 1.50 g (10 mmol) of compound 2 into a 250 ml round bottom flask, dissolve it in 80 ml of CCl4, then add 1.98 g (11 mmol) of NBS and 48 mg (0.2 mmol) of BPO and heat and reflux for 1.5 h to complete reaction. Remove the floating insolubles through filtration and then remove the solvent to obtain compound 3. The reaction is quantitative.
98% With N-Bromosuccinimide In tetrachloromethane for 2 h; Heating / reflux 50 g of methyl 2-methylbenzoate (0.33 M), 60.4 g of N-bromosuccinimide (0.340 M) and 4 g of benzoyl peroxide are added to a 2000 ml reactor containing 1500 ml of carbon tetrachloride. The reaction mixture is refluxed for 2 hours. After cooling to room temperature, the reaction medium is concentrated under vacuum. The oil obtained is purified by chromatography on silica (eluent: ChbCb). 74.5 g of a colourless oil are obtained (98percent yield).TLC: diisopropyl ether/petroleum ether (50/50).NMR (5 in ppm, DMSO, 200 MHz): 4.12 (s, 3H); 5.27 (s, 2H); 7.39 (d, 3H); 7.70 (d, 1H).IR (cm-1): 1720, 1577, 1269, 1294.
89% With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) In chloroform for 16 h; Heating / reflux 2-Methyl-benzoic acid methyl ester (1.50 g 10 mmol), N-bromo-succinimide (1.96 g, 11 mmol) and 2,2'-azobis(2-methyl-propionitrile) (AIBN) (25 mg, 0.15 mmol) were dissolved in chloroform (3 ml). The solution was heated at reflux for 16 hours cooled and the solvent evaporated in vacuo. The residue was purified by silica gel chromatography using a gradient of ethyl acetate/hexane (1-2 percent) as eluent. Pure fractions were collected and the solvent evaporated in vacuo affording 2.05 g (89 percent) of 2-bromomethyl-benzoic acid methyl ester as a solid. 1H-NMR (CDCl3): δ 7.97 (d, 1H, J = 7.6 Hz), 7.45-7.52 (m, 2H), 7.38 (dt, 1H, J = 1.2 Hz and J = 7.6 Hz), 4.96 (s, 2H), 3.95 (s, 1H). To a solution of 2-amino-5-(S)-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (100 mg, 0.20 mmol) and pyridine (0.18 ml, 2.0 mmol) in acetonitrile (1 ml) at room temperature was added benzyl chloroformate (0.28 ml, 2.0 mmol) in 10 aliquots over 48 hours. The solution was then taken into ethyl acetate (30 ml), washed with 0.5 N hydrochloric acid (3x10 ml), saturated sodium bicarbonate (3 x 10 ml), brine (10 ml), dried (MgSO4) and filtered. The solvent was evaporated in vacuo. The resulting oil crystallized upon standing for 2 days. The precipitate was filtered off and washed with diethyl ether (3 x 1 ml) affording after drying in vacuo 59 mg (47 percent) of 2-benzyloxy-carbonylamino-5-(S)-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid. 1H-NMR (CDCl3): δ 10.60 (s, 1H), 7.60-7.92 (m, 4H), 7.38 (m, 5H), 5.26 (s, 2H), 4.30-5.10 (m, 3H), 3.40-4.00 (m, 2H), 1.57 (m, 9H), 1.15 (m, 9H). To a solution of 1 N hydrochloric acid in ethyl acetate (1.0 ml) was added 2-benzyloxy-carbonylamino-5-(S)-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (52 mg, 0.08 mmol). The solution was stirred at room temperature for 48 hours. A precipitate was filtered off which afforded 42 mg (90 percent) of 2-benzyloxy-carbonylamino-5-(S)-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester hydrochloride as a solid. 1H-NMR (DMSO-d6): δ 10.45 (s, 1H), 9.40 (s, 1H), 9.25 (s, 1H), 7.89 (m, 4H), 7.39 (m, 5H), 5.22 (s, 2H), 4.39 (d, 1H, J = 15 Hz), 4.28 (m, 1H), 3.95 (m, 2H), 3.79 (m, 1H), 3.20 (m, 1H), 2.70 (m, 1H), 1.48 (s, 9H). To a solution of the above 2-benzyloxy-carbonylamino-5-(S)-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester hydrochloride (42 mg, 0.072 mmol) in ethanol (0.5 ml) was added hydrazine (68 μl, 0.22 mmol). The solution was stirred at 80 °C for 5 hours and at room temperature for 16 hours. The mixture was filtered and the filtrate evaporated in vacuo. The residue was extracted with dichloromethane (5 x 1 ml). The combined dichloromethane washes were evaporated in vacuo affording 20 mg (67 percent) of 5-(S)-aminomethyl-2-benzyloxy-carbonylamino-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester as an oil. 1H-NMR (CDCl3): δ 10.55 (bs, 1H), 7.37 (m, 5H), 5.23 (s, 2H), 3.92 (s, 2H), 2.60-3.10 (m, 3H), 1.53 (s, 9H). To a solution of the above 5-(S)-aminomethyl-2-benzyloxy-carbonylamino-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester (20 mg, 0.048 mmol) in acetonitrile (1 ml) at 0 °C was added diisopropylethylamine (18 l, 0.15 mmol) and 2-bromomethyl-benzoic acid methyl (12 mg, 0.048 mmol). The solution was stirred at 0 °C for 3 hours and at room temperature for 16 hours. Di-tert-butyl dicarbonate (21 mg, 0.096 mmol) was then added to the solution. The solution was then stirred at room temperature for 16 hours. The solution was taken into ethyl acetate (30 ml), washed with 0.5 N hydrochloric acid (3 x 10 ml), saturated sodium bicarbonate (3 x 10 ml) and brine (10 ml), dried (MgSO4) and filtered. The solvent was evaporated in vacuo. The solid residue was purified by silica gel chromatography using a 5 percent mixture of ethyl acetate/hexane as eluent. Pure fractions were collected and the solvent evaporated in vacuo affording 10 mg (33 percent) of 2-(benzyloxycarbonylamino)-5-(S)-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid. 1H-NMR (CDCl3): δ 10.59 (s, 1H), 7.81 (m, 1H), 7.52 (m, 1H), 7.39 (m, 7H), 5.25 (s, 1H), 4.22-5.00 (m, 4H), 4.40-4.80 (m, 2H), 2.80-3.10 (m, 2H), 1.55 (s, 9H), 1.25 (s, 9H). To a solution of the above 2-benzytoxycarbonylamino-5-(S)-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (9 mg, 0.014 mmol) in methanol (2 ml) was added 10 percent Pd/C (4 mg). The mixture was stirred under hydrogen (1 atm.) for 3 hours and then filtered. The filtrate was evaporated in vacuo affording 6 mg (93 percent) of 2-amino-5-(S)-(1 -oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid. 1H-NMR (CDCl3): δ 7.80 (m, 1H), 7.50 (m, 1H), 7.44 (m, 2H), 4.22-5.00 (m, 4H), 4.40-4.80 (m, 2H), 2.80-3.10 (m, 2H), 1.63 (s, 9H), 1.25 (s, 9H). To a solution of the above 2-amino-5-(S)-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (6 mg, 0.013 mmol) in acetonitrile (0.5 ml) at room temperature was added imidazol-1-yl-oxo-acetic acid tert-butyl ester (27 mg, 0.13 mmol). The solution was stirred for 3 hours at room temperature and then diluted with ethyl acetate (20 ml), washed with 0.5 N hydrochloric acid (2 x 5 ml), saturated sodium bicarbonate (2 x 5 ml), brine (5 ml), dried (MgSO4) and filtered. The solvent was evaporated in vacuo. The residue was purified by silica gel chromatography using a gradient of ethyl acetate/hexane (10-25 percent gradient) as eluent. Pure fractions were collected and the solvent evaporated in vacuo affording 4 mg (50 percent) of 2-(tert-butoxyoxalyl-amino)-5-(S)-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid. 1H-NMR (CDCl3): δ 12.49 (s, 1H), 7.80 (m, 1H), 7.50 (m, 1H), 7.44 (m, 2H), 4.22-5.00 (m, 4H), 4.20-4.90 (m, 2H), 2.90-3.20 (m, 2H), 1.63 (s, 9H), 1.60 (s, 9H), 1.25 (s, 9H). To a solution of trifluoroacetic acid/dichloromethane (0.5 ml, 1:1) at room temperature was added the above 2-(tert-butoxyoxalyl-amino)-5-(S)-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (4 mg, 0.006 mmol). The solution was stirred for 3 hours. The solvent was removed in vacuo. The residue was washed with dichloromethane affording in quantitative yield the title compound as a solid trifluoroacetate. 1H-NMR (DMSO-d6): δ 12.32 (s, 1H), 4.62 (s, 1H), 4.12 (m, 1H), 3.62-3.78 (m, 2H), 3.40-3.52 (m, 1H), 2.83 (m, 2H). MS: m/z: 416 [M+H]+.
89% With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) In chloroform for 16 h; Heating / reflux Example 53 2-(Oxalyl-amino)-5-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid; 2-Methyl-benzoic acid methyl ester (1.50 g 10 mmol), N-bromosuccinimide (1.96 g, 11 mmol) and 2,2'-azobis(2-methylpropionitrile) (AIBN) (25 mg, 0.15 mmol) were dissolved in chloroform (3 ml). The solution was heated at reflux for 16 h. cooled and the solvent evaporated in vacuo. The residue was purified by silica gel chromatography using a gradient of ethyl acetate/hexane (1-2percent) as eluant. Pure fractions were collected and the solvent evaporated in vacuo affording 2.05 g (89percent) of 2-bromomethyl-benzoic acid methyl ester as a solid.1H NMR (CDCl3): δ 7.97 (d, 1H, J=7.6 Hz), 7.45-7.52 (m, 2H), 7.38 (dt, 1H, J=1.2, 7.6 Hz), 4.96 (s, 2H), 3.95 (s, 1H).To a solution of 2-amino-5-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (100 mg, 0.20 mmol) and pyridine (0.18 ml, 2.0 mmol) in acetonitrile (1 ml) at room temperature was added benzyl chloroformate (0.28 ml, 2.0 mmol) in 10 aliquots over 48 h. The solution was then taken into ethyl acetate (30 ml), washed with 0.5 N hydrochloric acid (3.x.10 ml), saturated sodium bicarbonate (3.x.10 ml), brine (10 ml), dried (MgSO4) and filtered. The solvent was evaporated in vacuo. The resulting oil crystallized upon standing for 2 days. The precipitate was filtered off and washed with diethyl ether (3.x.1 ml) affording after drying in vacuo 59 mg (47,percent) of 2-benzyloxy-carbonylamino-5-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid.1H NMR (CDCl3): δ 10.60 (s, 1H), 7.60-7.92 (m, 4H), 7.38 (m, 5H), 5.26 (s, 2H), 4.30-5.10 (m, 3H), 3.40-4.00 (m, 2H), 1.57 (m, 9H), 1.15 (m, 9H).To a solution of 1N hydrochloric acid in ethyl acetate (1.0 ml) was added 2-benzyloxy-carbonylamino-5-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (52 mg, 0.08 mmol). The solution was stirred at room temperature for 48 h. A precipitate was filtered off which afforded 42 mg (90percent) of 2-benzyloxy-carbonylamino-5-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester hydrochloride as a solid.1H NMR (DMSO-d6): 810.45 (s, 1H), 9.40 (s, 1H), 9.25 (s, 1H), 7.89 (m, 4H), 7.39 (m, 5H), 5.22 (s, 2H), 4.39 (d, 1H, J=15 Hz), 4.28 (m, 1H), 3.95 (m, 2H), 3.79 (m, 1H), 3.20 (m, 1H), 2.70 (m, 1H), 1.48 (s, 9H).To a solution of the above 2-benzyloxy-carbonylamino-5-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester hydrochloride (42 mg, 0.072 mmol) in ethanol (0.5 ml) was added hydrazine (68 μl, 0.22 mmol). The solution was stirred at 80° C. for 5 h. and at room temperature for 16 h. The mixture was filtered and the filtrate evaporated in vacuo. The residue was extracted with dichloromethane (5.x.1 ml). The combined dichloromethane washes were evaporated in vacuo affording 20 mg (67percent) of 5-aminomethyl-2-benzyloxy-carbonylamino-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester as an oil.1H NMR (CDCl3): δ 10.55 (bs, 1H), 7.37 (m, 5H), 5.23 (s, 2H), 3.92 (s, 2H), 2.60-3.10 (m, 3H), 1.53 (s, 9H).To a solution of the above 5-aminomethyl-2-benzyloxy-carbonylamino-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3-carboxylic acid tert-butyl ester (20 mg, 0.048 mmol) in acetonitrile (1 ml) at 0° C. was added diisopropylethylamine (18 μl, 0.15 mmol) and 2-bromomethyl-benzoic acid methyl (12 mg, 0.048 mmol). The solution was stirred at 0° C. for 3 hours and at room temperature for 16 h. Di-tert-butyl dicarbonate (21 mg, 0.096 mmol) was then added to the solution. The solution was then stirred at room temperature for 16 h. The solution was taken into ethyl acetate (30 ml), washed with 0.5 N hydrochloric acid (3.x.10 ml), saturated sodium bicarbonate (3.x.10 ml) and brine (10 ml), dried (MgSO4) and filtered. The solvent was evaporated in vacuo. The solid residue was purified by silica gel chromatography using a 5percent mixture of ethyl acetate/hexane as eluant. Pure fractions were collected and the solvent evaporated in vacuo affording 10 mg (33percent) of 2-benzyloxycarbonylamino-5-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid.1H NMR (CDCl3): δ 10.59 (s, 1H), 7.81 (m, 1H), 7.52 (m, 1H), 7.39 (m, 7H), 5.25 (s, 1H), 4.22-5.00 (m, 4H), 4.40-4.80 (m, 2H), 2.80-3.10 (m, 2H), 1.55 (s, 9H), 1.25 (s, 9H).To a solution of the above 2-benzyloxycarbonylamino-5-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (9 mg, 0.014 mmol) in methanol (2 ml) was added 10percent Pd/C (4 mg). The mixture was stirred under hydrogen (1 atm.) for 3 hours and then filtered. The filtrate was evaporated in vacuo affording 6 mg (93percent) of 2-amino-5-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid.1H NMR (CDCl3): δ 7.80 (m, 1H), 7.50 (m, 1H), 7.44 (m, 2H), 4.22-5.00 (m, 4H), 4.40-4.80 (m, 2H), 2.80-3.10 (m, 2H), 1.63 (s, 9H), 1.25 (s, 9H).To a solution of the above 2-amino-5-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester (6 mg, 0.013 mmol) in acetonitrile (0.5 ml) at room temperature was added imidazol-1-yl-oxo-acetic acid tert-butyl ester (27 mg, 0.13 mmol). The solution was stirred for 3 hours at room temperature and then diluted with ethyl acetate (20 ml), washed with 0.5 N hydrochloric acid (2.x.5 ml), saturated sodium bicarbonate (2.x.5 ml), brine (5 ml), dried (MgSO4) and filtered. The solvent was evaporated in vacuo: The residue was purified by silica gel chromatography using a gradient of ethyl acetate/hexane (10-25percent gradient) as eluant. Pure fractions were collected and the solvent evaporated in vacuo affording 4 mg (50percent) of 2-(tert-butoxyoxalyl-amino-5-(1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-4,5,6,7-tetrahydro-thieno[2,3-c]pyridine-3,6-dicarboxylic acid di-tert-butyl ester as a solid.1H NMR (CDCl3): δ 12.49 (s, 1H), 7.80 (m, 1H), 7.50 (m, 1H), 7.44 (m, 2H), 4.22-5.00 (m, 4H), 4.20-4.90 (m, 2H), 2.90-3.20 (m, 2H), 1.63 (s, 9H), 1.60 (s, 9H), 1.25 (s, 9H).
80% With N-Bromosuccinimide In tetrachloromethaneReflux A solution of compound 18b (4.5 g, 30 mmol), NBS (5.9 g, 33 mmol) and AIBN (0.5 g, 3 mmol) in CCI4 (20 mL) was refluxed overnight. The mixture was taken up in H20 (20 mL) and extracted with DCM (100 mL). The organic layer was washed with brine, dried over Na2S04, filtered and concentrated. The crude product was purified by CC to give the compound 18c (5.5 g, 80percent yield).
77% With N-Bromosuccinimide; dibenzoyl peroxide In tetrachloromethane for 4 h; Heating / reflux To a solution of methyl 2-methylbenzoate (5g, 0. 033mol) in carbon tetrachloride (85ml) was added n-bromosuccinimide (5.93g, 0. 033mol) and benzoyl peroxide (0.22g, 0. 9mol). The reaction was refluxed for 4 hr. The reaction was cooled to room temperature. The white precipitate was filtered and the solvent removed. The oil was dissolved in ET2O and cooled to-78°C The product precipitated and collected yielding v (5. 86G, 77percent).
68% With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) In tetrachloromethane at 85℃; for 17 h; Reflux; Inert atmosphere A mixture of Methyl 2-methylbenzoate (1.00 mL, 7.20 mmol)and NBS (1.40 g, 7.90 mmol) in CCl4 (28 mL) was degassed. AIBN(24.0 mg, 0.140 mmol) was added and the mixture was heatedto 85 C for 16 h. Further NBS (0.130 g, 0.710 mmol) was addedand the whole was refluxed for 1 more hour. The mixture wasdiluted with CH2Cl2 and washed with sat. aq NaHCO3 solutionand water. The organic layer was dried (Na2SO4), filtered and concentratedin vacuo. Purification of the residue by flash chromatography(hexane/EtOAc 100:0?95:5) gave the title compound as anorange to pink liquid that solidifies on standing (68percent). 1H NMR(300 MHz, CDCl3) d ppm 3.92 (s, 3H), 4.95 (s, 2H), 7.30–7.39 (m,1H), 7.41–7.53 (m, 2H), 7.89–8.01 (m, 1H). 13C NMR (75 MHz,CDCl3) d ppm 31.7, 52.4, 128.7, 129.2, 131.4, 131.8, 132.7, 139.4,167.2.
67.6% With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) In chloroform at 85℃; Reflux A mixture of Methyl 2-methylbenzoate (1 mL, 7.2 mmol) and NBS (1.4 g, 7.9 mmol) in 0014 (28 mL) was degassed. AIBN (24 mg, 0.14 mmol) was added and the mixture was heated to 85 00 overnight. Eurther NBS (0.13 g, 0.71 mmol) was added and the whole was refluxed for 1 more hour. The mixture was diluted with 0H2012 and washed with sat. aq. NaHOO3 solution andwater. The organic layer was dried (Na2SO4), filtered and concentrated in vacuo. Purification of the residue by flash chromatography (hexane/EtOAc 100:0 —* 95:5) gave the title compound as an orange to pink liquid that solidifies on standing (67.6percent). 1H NMR (300 MHz, ODd3) 6 ppm 3.92 (s, 3 H) 4.95 (s, 2 H) 7.30 - 7.39 (m, 1 H) 7.41 - 7.53 (m, 2 H) 7.89 - 8.01 (m, 1 H). 130 NMR (75 MHz, 0D013)6 ppm 31.7, 52.4, 128.7, 129.2, 131.4, 131.8, 132.7, 139.4, 167.2.
65.7% With N-Bromosuccinimide; 2,2'-azobis(isobutyronitrile) In acetonitrile at 90℃; for 6 h; Inert atmosphere To a stirred solution of methyl 2-methylbenzoate 6- 1 A (5 g, 33.3 mmol) in ACN (200 mL) was added NBS (5.3 g, 30 mmol) and AIBN (547 mg, 3.33 mmol) at RT. The reaction mixture was warmed to 90 °C for 6 hr under nitrogen atmosphere. The reaction mixture solvent was evaporated under reduced pressure and the crude residue washed with toluene (500 mL) and filtered the precipitate (NBS). Filtrate evaporated under reduced pressure and the crude residue was purified by flash column chromatography (100-200 silica) using 2percent EtOAc/pet. ether to afford 6-2A (5 g, 22.1 mmol, 65.7 percent yield) as a yellow thick liquid.
62% With N-Bromosuccinimide In chloroformReflux To a solution of methyl 2-(methyl)benzoate 3a (9.46 g, 6.3 mmol) in chloroform (200 mL) were added NBS (13.8 g, 7.6 mmol) and benzoyl peroxide (760 mg, 0.32 mmol). The reaction mixture was stirred at reflux overnight. When the mixture was cooled to rt, filtered and concentrated. The residue was purified by CC, eluted with PE to give 3b as a colorless oil (9 g, 62percent yield).
62% With N-Bromosuccinimide; dibenzoyl peroxide In chloroformReflux To a solution of compound 3a (9.46 g, 6.3 mmol) in chloroform (200 mL) were added NBS (13.8 g, 7.6 mmol) and benzoyl peroxide (760 mg, 0.32 mmol).
The reaction mixture was stirred at reflux overnight.
When the mixture was cooled to room temperature, it was filtered and the filtrate was concentrated.
The residue was purified by silica gel chromatography, eluted with petroleum ether to give 3b as a colorless oil (Yield: 9 g, 62percent).
37% With N-Bromosuccinimide; dibenzoyl peroxide In tetrachloromethaneHeating / reflux A mixture of methyl o-toluate (13.5 g, 89.9 mmol), NBS (17.6 g, 98.9 mmol), and benzoyl peroxide (50 mg, 0.2 mmol) in carbon tetrachloride (250 mL) was heated at reflux over the weekend. The reaction mixture was allowed to cool, and it was then filtered. The solvents were evaporated under reduced pressure and the residue was purified by chromatography, eluting with 3percent ethyl acetate/hexanes to give 2-bromomethyl-benzoic acid methyl ester (7.7 g, 37percent) as a white solid. 1HNMR (CDCl3): δ 7.97 (dd, J=1.5 Hz, 8.0 Hz, 1H), 7.49 (m, 2H), 7.38 (dt, J=1.5 Hz, 8.0 Hz, 1H), 4.96 (s, 2H), 3.94 (s, 3H). MS (APCI+): 231 (100), 229 (93).
7 g With N-Bromosuccinimide; dibenzoyl peroxide In tetrachloromethane for 2 h; Reflux The o-methylbenzoate (6 g, 39.95 mmol) was weighed into 60 mL of carbon tetrachloride and NBS(2.73 g, 47.94 mmol) and benzoyl peroxide (484 mg, 2 mmol) and refluxed for 2 h. TLC detectionAfter completion of the reaction, the reaction solution was cooled, filtered and the filtrate was dried to give intermediate o-bromomethylbenzoic acid methyl ester (7 g).

Reference: [1] Journal of Medicinal Chemistry, 2000, vol. 43, # 24, p. 4667 - 4677
[2] Chemical Communications, 2010, vol. 46, # 13, p. 2227 - 2229
[3] Patent: US2011/237786, 2011, A1, . Location in patent: Page/Page column 7
[4] Zeitschrift fuer Naturforschung, B: Chemical Sciences, 1989, vol. 44, # 9, p. 1132 - 1148
[5] Journal of Heterocyclic Chemistry, 1980, vol. 17, # 9, p. 1359 - 1360
[6] Chemische Berichte, 1987, vol. 120, p. 1151 - 1174
[7] Patent: WO2006/288, 2006, A1, . Location in patent: Page/Page column 64-65
[8] Tetrahedron Letters, 2010, vol. 51, # 13, p. 1793 - 1796
[9] Organic and Biomolecular Chemistry, 2011, vol. 9, # 12, p. 4432 - 4435
[10] Patent: EP1214324, 2006, B1, . Location in patent: Page/Page column 30-32
[11] Patent: US7115624, 2006, B1, . Location in patent: Page/Page column 114-116
[12] Monatshefte fuer Chemie, 1992, vol. 123, # 10, p. 939 - 948
[13] Monatshefte fur Chemie, 2003, vol. 134, # 7, p. 991 - 1014
[14] Journal of Organic Chemistry, 2000, vol. 65, # 16, p. 5037 - 5042
[15] Heterocyclic Communications, 2001, vol. 7, # 5, p. 449 - 454
[16] Tetrahedron Letters, 1982, vol. 23, # 10, p. 1031 - 1034
[17] Journal of Medicinal Chemistry, 1999, vol. 42, # 10, p. 1767 - 1777
[18] Patent: WO2011/107248, 2011, A1, . Location in patent: Page/Page column 57
[19] Patent: WO2004/101506, 2004, A1, . Location in patent: Page 51
[20] Journal of Medicinal Chemistry, 1993, vol. 36, # 26, p. 4230 - 4238
[21] Bioorganic and Medicinal Chemistry Letters, 1998, vol. 8, # 24, p. 3683 - 3688
[22] Journal of Organic Chemistry, 2017, vol. 82, # 2, p. 1114 - 1126
[23] Organic Letters, 2013, vol. 15, # 4, p. 917 - 919
[24] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 19, p. 4563 - 4575
[25] Patent: WO2016/5340, 2016, A1, . Location in patent: Page/Page column 152
[26] Patent: WO2016/154241, 2016, A1, . Location in patent: Paragraph 337; 338
[27] Journal of Organic Chemistry, 2002, vol. 67, # 7, p. 2160 - 2167
[28] Patent: WO2011/107248, 2011, A1, . Location in patent: Page/Page column 39
[29] Patent: EP2368886, 2011, A1, . Location in patent: Paragraph 0096
[30] Journal of Medicinal Chemistry, 1987, vol. 30, # 1, p. 96 - 104
[31] Patent: US2004/266856, 2004, A1, . Location in patent: Page/Page column 18
[32] Journal of Organic Chemistry, 1952, vol. 17, p. 1252,1255
[33] Journal of the Chemical Society, 1965, vol. 65, p. 1829 - 1843
[34] Journal of the American Chemical Society, 1962, vol. 84, p. 1179 - 1185
[35] Journal of Medicinal Chemistry, 1992, vol. 35, # 7, p. 1200 - 1209
[36] Tetrahedron Letters, 1993, vol. 34, # 41, p. 6599 - 6602
[37] Journal of Medicinal Chemistry, 1986, vol. 29, # 11, p. 2347 - 2351
[38] Journal of Medicinal Chemistry, 1992, vol. 35, # 11, p. 1954 - 1968
[39] Tetrahedron Letters, 2001, vol. 42, # 6, p. 1069 - 1072
[40] Tetrahedron, 2002, vol. 58, # 17, p. 3361 - 3370
[41] Tetrahedron Letters, 2003, vol. 44, # 38, p. 7209 - 7212
[42] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 6, p. 1532 - 1536
[43] Journal of Medicinal Chemistry, 2006, vol. 49, # 26, p. 7912 - 7915
[44] Journal of Medicinal Chemistry, 2003, vol. 46, # 3, p. 345 - 348
[45] Journal of Organic Chemistry, 2001, vol. 66, # 24, p. 8165 - 8176
[46] Synthesis, 2006, # 15, p. 2556 - 2562
[47] Organic and Biomolecular Chemistry, 2007, vol. 5, # 1, p. 103 - 113
[48] Patent: US2005/143348, 2005, A1, . Location in patent: Page/Page column 54
[49] Patent: US2003/114435, 2003, A1,
[50] Patent: US4552585, 1985, A,
[51] Patent: US6251898, 2001, B1,
[52] Patent: WO2006/128142, 2006, A2, . Location in patent: Page/Page column 41
[53] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 5, p. 1628 - 1631
[54] Patent: WO2005/103022, 2005, A1, . Location in patent: Page/Page column 112
[55] European Journal of Organic Chemistry, 2010, # 3, p. 555 - 564
[56] Patent: US2007/197512, 2007, A1, . Location in patent: Page/Page column 55
[57] Patent: US2010/286225, 2010, A1, . Location in patent: Page/Page column 4
[58] Angewandte Chemie - International Edition, 2011, vol. 50, # 22, p. 5075 - 5080
[59] Patent: WO2011/48082, 2011, A1, . Location in patent: Page/Page column 85; 86
[60] Patent: EP2386563, 2011, A1, . Location in patent: Page/Page column 22-23
[61] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 2, p. 814 - 819
[62] Chemistry - A European Journal, 2012, vol. 18, # 5, p. 1383 - 1400
[63] Tetrahedron, 2012, vol. 68, # 23, p. 4399 - 4405
[64] Tetrahedron Letters, 2012, vol. 53, # 28, p. 3654 - 3657
[65] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7862 - 7874
[66] Tetrahedron, 2013, vol. 69, # 49, p. 10581 - 10592
[67] ChemMedChem, 2014, vol. 9, # 1, p. 67 - 72
[68] Inorganic Chemistry, 2014, vol. 53, # 5, p. 2683 - 2691
[69] Organic and Biomolecular Chemistry, 2014, vol. 12, # 24, p. 4218 - 4232
[70] RSC Advances, 2015, vol. 5, # 2, p. 1438 - 1446
[71] Patent: WO2016/57924, 2016, A1, . Location in patent: Page/Page column 103; 104
[72] Patent: WO2016/62814, 2016, A1, . Location in patent: Page/Page column 102
[73] Bioorganic and Medicinal Chemistry Letters, 2016, vol. 26, # 10, p. 2526 - 2530
[74] Patent: CN105330639, 2016, A, . Location in patent: Paragraph 0083; 0084
[75] Patent: CN105523987, 2016, A, . Location in patent: Paragraph 0015; 0016; 0017
[76] Tetrahedron, 2017, vol. 73, # 20, p. 2913 - 2922
[77] ChemMedChem, 2018, vol. 13, # 15, p. 1530 - 1540
[78] Patent: WO2006/120010, 2006, A2, . Location in patent: Page/Page column 12; 38
  • 5
  • [ 89-71-4 ]
  • [ 2417-73-4 ]
YieldReaction ConditionsOperation in experiment
96% With dibenzoyl peroxide In tetrachloromethane Synthesis of 2-(Bromomethyl)benzoic acid methyl ester
2-Methylbenzoic acid methyl ester (582 mg, 3.88 mmol), N-bromosuccinimid (NBS) (759 mg, 4.26 mmol), and benzoyl peroxide (13 mg, 0.04 mmol) in CCl4 (10 mL) was stirred at reflux for 5 h.
After cooling to room temperature, the reaction mixture was extracted with CH2Cl2 (*3).
The extract was washed with brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuo.
The crude product was purified by flash chromatography on silica gel (Hex/EtOAc=9:1) to give 2-(bromomethyl)benzoic acid methyl ester (Formula 5) as a white solid (850 mg, 96percent). Rf=0.6 (Hex:EtOAc=9:1); 1H NMR (300 MHz, CDCl3): δ 7.97 (d, J=7.5 Hz, 1H), 7.48 (m, 2H), 7.38 (td, J=7.8 and 1.2 Hz, 1H), 4.96 (s, 2H), 3.95 (s, 3H).
[lit.2 δ 7.97 (m, 1H), 7.40 (m, 3H), 4.96 (s, 2H), 3.95 (s, 3H).
Reference: [1] Patent: US2010/240139, 2010, A1,
  • 6
  • [ 2094-98-6 ]
  • [ 89-71-4 ]
  • [ 2417-73-4 ]
YieldReaction ConditionsOperation in experiment
78% With N-Bromosuccinimide In tetrachloromethane EXAMPLE 33
COMPOUND 33: 2-(3,3"-Dimethyl-3',4',5',6'-tetrahydro-2'H-[2,2';6',2"]terpyridin-1'-ylmethyl)-benzoic Acid Methyl Ester
To a solution of 2-methyl-benzoic acid methyl ester (4.58 g, 30.5 mmol) in CCl4 (75 mL) was added N-bromosuccinimide (5.79 g, 32.5 mmol) followed by 1,1'-azobis(cyclohexanecarbonitrile) (1.42 g, 5.80 mmol).
The resultant mixture was refluxed for 6 hours then cooled to room temperature, filtered through filter paper, and concentrated.
Purification of the crude material by column chromatography on silica gel (20:1:hexanes-EtOAc) provided 5.44 g (78percent) of 2-bromomethyl-benzoic acid methyl ester as a colorles oil. 1H NMR (CDCl3) δ 3.95 (s, 3H), 4.96 (s, 2H), 7.36-7.50 (m, 3H), 7.97 (d, 1H, J=7.8 Hz).
Reference: [1] Patent: US2005/154201, 2005, A1,
  • 7
  • [ 89-71-4 ]
  • [ 74-95-3 ]
  • [ 2417-73-4 ]
Reference: [1] Patent: US2003/13743, 2003, A1,
  • 8
  • [ 89-71-4 ]
  • [ 2417-73-4 ]
  • [ 244219-99-6 ]
Reference: [1] Patent: US6410561, 2002, B1,
  • 9
  • [ 118-90-1 ]
  • [ 2417-73-4 ]
Reference: [1] Journal of Organic Chemistry, 1952, vol. 17, p. 1252,1255
[2] Patent: US2005/143348, 2005, A1, . Location in patent: Page/Page column 52
[3] Patent: US2011/237786, 2011, A1,
[4] Patent: WO2011/107248, 2011, A1,
  • 10
  • [ 67-56-1 ]
  • [ 40819-28-1 ]
  • [ 2417-73-4 ]
Reference: [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 1, p. 149 - 157
  • 11
  • [ 933-88-0 ]
  • [ 2417-73-4 ]
Reference: [1] Patent: US2011/237786, 2011, A1,
  • 12
  • [ 186581-53-3 ]
  • [ 7115-89-1 ]
  • [ 2417-73-4 ]
Reference: [1] Journal of Organic Chemistry, 1952, vol. 17, p. 1252,1255
  • 13
  • [ 7115-89-1 ]
  • [ 2417-73-4 ]
Reference: [1] Zhurnal Russkago Fiziko-Khimicheskago Obshchestva, 1914, vol. 46, p. 510[2] Chem. Zentralbl., 1914, vol. 85, # II, p. 1271
  • 14
  • [ 2417-73-4 ]
  • [ 55453-87-7 ]
Reference: [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 1, p. 246 - 252
  • 15
  • [ 2417-73-4 ]
  • [ 18469-52-8 ]
Reference: [1] Patent: EP1550657, 2005, A1, . Location in patent: Page/Page column 35
  • 16
  • [ 2417-73-4 ]
  • [ 55453-89-9 ]
Reference: [1] Journal of Medicinal Chemistry, 1996, vol. 39, # 1, p. 246 - 252
  • 17
  • [ 2417-73-4 ]
  • [ 1229-29-4 ]
Reference: [1] Patent: CN105367538, 2016, A,
[2] Patent: CN105367538, 2016, A,
[3] Patent: CN105367538, 2016, A,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 2417-73-4 ]

Aryls

Chemical Structure| 16281-97-3

[ 16281-97-3 ]

Methyl 4-(1-bromoethyl)benzoate

Similarity: 0.90

Chemical Structure| 108052-76-2

[ 108052-76-2 ]

tert-Butyl 4-(bromomethyl)benzoate

Similarity: 0.90

Chemical Structure| 6515-58-8

[ 6515-58-8 ]

3-(Bromomethyl)benzoic acid

Similarity: 0.89

Chemical Structure| 114772-38-2

[ 114772-38-2 ]

Methyl 2-[4-(Bromomethyl)phenyl]benzoate

Similarity: 0.88

Chemical Structure| 877624-40-3

[ 877624-40-3 ]

Methyl 3-bromo-5-(bromomethyl)benzoate

Similarity: 0.88

Bromides

Chemical Structure| 16281-97-3

[ 16281-97-3 ]

Methyl 4-(1-bromoethyl)benzoate

Similarity: 0.90

Chemical Structure| 108052-76-2

[ 108052-76-2 ]

tert-Butyl 4-(bromomethyl)benzoate

Similarity: 0.90

Chemical Structure| 6515-58-8

[ 6515-58-8 ]

3-(Bromomethyl)benzoic acid

Similarity: 0.89

Chemical Structure| 114772-38-2

[ 114772-38-2 ]

Methyl 2-[4-(Bromomethyl)phenyl]benzoate

Similarity: 0.88

Chemical Structure| 877624-40-3

[ 877624-40-3 ]

Methyl 3-bromo-5-(bromomethyl)benzoate

Similarity: 0.88

Esters

Chemical Structure| 16281-97-3

[ 16281-97-3 ]

Methyl 4-(1-bromoethyl)benzoate

Similarity: 0.90

Chemical Structure| 108052-76-2

[ 108052-76-2 ]

tert-Butyl 4-(bromomethyl)benzoate

Similarity: 0.90

Chemical Structure| 78471-43-9

[ 78471-43-9 ]

Methyl 4-bromo-2-bromomethylbenzoate

Similarity: 0.88

Chemical Structure| 114772-38-2

[ 114772-38-2 ]

Methyl 2-[4-(Bromomethyl)phenyl]benzoate

Similarity: 0.88

Chemical Structure| 877624-40-3

[ 877624-40-3 ]

Methyl 3-bromo-5-(bromomethyl)benzoate

Similarity: 0.88

Benzyl Bromides

Chemical Structure| 16281-97-3

[ 16281-97-3 ]

Methyl 4-(1-bromoethyl)benzoate

Similarity: 0.90

Chemical Structure| 108052-76-2

[ 108052-76-2 ]

tert-Butyl 4-(bromomethyl)benzoate

Similarity: 0.90

Chemical Structure| 6515-58-8

[ 6515-58-8 ]

3-(Bromomethyl)benzoic acid

Similarity: 0.89

Chemical Structure| 114772-38-2

[ 114772-38-2 ]

Methyl 2-[4-(Bromomethyl)phenyl]benzoate

Similarity: 0.88

Chemical Structure| 877624-40-3

[ 877624-40-3 ]

Methyl 3-bromo-5-(bromomethyl)benzoate

Similarity: 0.88